About EyeGene
EyeGene is a company based in Seoul (South Korea) founded in 2000.. The company has 50 employees as of December 31, 2024. EyeGene offers products and services including Pharmaceutical Wholesale Service and Medical Device Business. EyeGene operates in a competitive market with competitors including Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others.
- Headquarter Seoul, South Korea
- Employees 50 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Eyegene, Inc.
-
Annual Revenue
$2.28 M (USD)7.37as on Dec 31, 2024
-
Net Profit
$-8.22 M (USD)42.54as on Dec 31, 2024
-
EBITDA
$-7.4 M (USD)56.27as on Dec 31, 2024
-
Latest Funding Round
$11.54 M (USD), Post-IPO
Dec 13, 2017
-
Investors
Korea Investment Holdings
& 3 more
-
Employee Count
50
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of EyeGene
EyeGene is a publicly listed company on the KRX with ticker symbol 185490 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of EyeGene
EyeGene offers a comprehensive portfolio of products and services, including Pharmaceutical Wholesale Service and Medical Device Business. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Provides distribution of pharmaceuticals to business clients in healthcare.
Offers devices for therapeutic applications in ischemic and vaccine fields.
Funding Insights of EyeGene
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $11.5M
- First Round First Round
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2017 | Amount | Post-IPO - EyeGene | Valuation |
investors |
|
| Jun, 2013 | Amount | Private Equity Round - EyeGene | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in EyeGene
EyeGene has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Korea Investment Holdings, DSC Investment and LB Investment. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage venture capital is invested primarily in South Korean startups.
|
Founded Year | Domain | Location | |
|
Investment holding firm established in Seoul in 2003.
|
Founded Year | Domain | Location | |
|
Venture capital investments in startups, focusing on growth and value creation in various industries.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by EyeGene
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - EyeGene
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Eyegene Comparisons
Competitors of EyeGene
EyeGene operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, Aldeyra, Nicox and Gyroscope, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for the treatment of diabetes
|
|
| domain | founded_year | HQ Location |
Developer of antibodies to treat complement-mediated neurodegenerative diseases
|
|
| domain | founded_year | HQ Location |
Drug candidates for immune-mediated diseases are developed by Aldeyra.
|
|
| domain | founded_year | HQ Location |
Nitric oxide-based therapeutics for glaucoma and eye conditions are developed.
|
|
| domain | founded_year | HQ Location |
Mobile SDK developed for app engagement and monetization strategies.
|
|
| domain | founded_year | HQ Location |
Gene therapies for ocular and neurodegenerative diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Eyegene
Frequently Asked Questions about EyeGene
When was EyeGene founded?
EyeGene was founded in 2000 and raised its 1st funding round 13 years after it was founded.
Where is EyeGene located?
EyeGene is headquartered in Seoul, South Korea.
How many employees does EyeGene have?
As of Dec 31, 2024, the latest employee count at EyeGene is 50.
What is the annual revenue of EyeGene?
Annual revenue of EyeGene is $2.28M as on Dec 31, 2024.
What does EyeGene do?
EyeGene is focussed on developing drugs and diagnostic tests for ocular diseases based on the technology involving proteomics and immunology. Its pipeline includes EG-Mirotin, a biologic drug that targets to alleviate symptoms and treat non-proliferative diabetic retinopathy (phase 2a); EG-Decorin, a therapeutic ointment based on human derived recombinant peptide for the treatment of pressure ulcers caused by Ischemianbsp;(phase 12); EG-HPV, a vaccine for cervical cancer (phase 2) and EGS, an ophthalmic anti-scarring agent and EGVac, an immune adjuvant derived from a combination of bacterial DNA. It is also developing Diabetic Retinopathy detection kit which has two techniques namely detecting the antibodies formed by vascular disruption and the diagnosis utilizing SNP sequences for VEGF receptors.
Who are the top competitors of EyeGene?
EyeGene's top competitors include Annexon, Alimera Sciences and MeiraGTx.
What products or services does EyeGene offer?
EyeGene offers Pharmaceutical Wholesale Service and Medical Device Business.
Is EyeGene publicly traded?
Yes, EyeGene is publicly traded on KRX under the ticker symbol 185490.
Who are EyeGene's investors?
EyeGene has 4 investors. Key investors include Korea Investment Holdings, DSC Investment, LB Investment, and GNTECHVC.
What is EyeGene's ticker symbol?
The ticker symbol of EyeGene is 185490 on KRX.